UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Apr

    18

    How Shared Decision-Making Creates Better Patient-Provider Collaboration in Dermatology

    Read More

    Apr

    17

    UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

    Read More

    Apr

    14

    Recognizing UCB’s Rising Stars: Brittany Blair and Lauren Drowley Recognized by the Healthcare Businesswomen’s Association

    Read More

    Mar

    17

    Exploring the future of dermatology at AAD 2023

    Read More

    Mar

    16

    You Speak, We Listen: How Community Voices Drive Our Work in HS

    Read More

    Feb

    17

    Patient-First, Patient-Focused: Our Purpose and Promise

    Read More

    Jan

    20

    Employee Spotlight: Ian Crassweller – Leading and Evolving Through Change

    Read More

    Jan

    18

    Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

    Read More

    Jan

    06

    UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

    Read More